Financial Results for the Fiscal Year
Ended March 31, 2023 and
Medium-Term Management Plan 2026
May 16, 2023
This is an English translation from Japanese presentation material.
Contents
- Consolidated Financial Results for the Fiscal Year Ended March 31, 2023
- Consolidated Financial Forecasts for the Year Ending March 31, 2024
- Review of Medium-Term Management Plan 2023
- Overview of Medium-Term Management Plan 2026
1
Consolidated Financial Results of FY2023
(for the Year Ended March 31, 2023): Sales (1)
Net | Y/Y | Comparison | ||
sales | with Feb. 9 | |||
(¥m) | forecast | |||
Reagents | 65,925 | +13,446 | ▲349 | |
+25.6% | ▲0.5% | |||
C O V I D | 35,901 | +10,262 | ▲188 | |
+40.0% | ▲0.5% | |||
General | 30,024 | +3,183 | ▲161 | |
research | +11.9% | ▲0.5% | ||
Reagents: Significant growth in sales of COVID reagents, and sales of general research reagents were firm.
currency | COVID | General | Overall |
research | |||
Local | |||
basis | |||
Japan
US
China
Europe
Overall
2 | ¥m: millions of yen | (Note) Explanation of year-on-year changes |
Consolidated Financial Results of FY2023
(for the Year Ended March 31, 2023) : Sales (2)
Net | Y/Y | Comparison | ||
(¥m) | sales | with Feb. 9 | ||
Forecast | ||||
Instruments | 1,375 | ▲142 | ▲174 | |
▲9.4% | ▲11.3% | |||
CDMO | 8,200 | ▲3,226 | ▲42 | |
▲28.2% | ▲0.5% | |||
Regenerative | 4,469 | ▲1,394 | ▲21 | |
medicine | ▲23.8% | ▲0.5% | ||
Gene Analysis/ | 3,732 | ▲1,832 | ▲21 | |
Testing & others | ▲32.9% | ▲0.6% | ||
Gene | 2,640 | +365 | +8 | |
Therapy | +16.1% | +0.3% | ||
Instruments: Sales of cell-analysis equipment increased. Sales of PCR equipment decreased.
CDMO: Sales decreased due to contraction of contracts related to COVID vaccines in the previous fiscal year
Gene analysis and testing: Revenues declined due to the contraction of a large-scalegenome analysis project led by the Japanese government in the previous fiscal year
Gene Therapy: Sales of RetroNectin® and other AM* increased
3 | *AM: Ancillary Materials | (Note: Explanation of all year-on-year changes) |
Consolidated Financial Results
for the Fiscal Year Ended March 2023
FY2023 | Y/Y | Comparison | ||||
Full year | with Feb. 9 | |||||
(¥m) | forecast | |||||
Net Sales | 78,142 | +10,442 | ▲ | |||
▲ | 557 | Grossprofit | ||||
+15.4% | 0.7% | |||||
▲ | ▲ | |||||
Gross | 44,765 | 4,445 | 291 | |||
profit | ▲ | ▲ | 0.6% | |||
9.0% | ||||||
Operating | 20,541 | ▲ | 8,360 | +541 | ||
profit | ▲28.9% | +2.7% | ||||
R&D | 8,575 | +2,466 | ▲78 | |||
expenses | +40.4% | ▲0.9% | ||||
4 |
Operating profit (Y/Y)
FY2022 289
Sales | +45 | ||
Composition | ▲118 | ||
Exchange | +29 | ||
R&D | ▲24 | ||
Personnel* | ▲8 | ||
Other | ▲7 |
FY2023 205
(¥100m)1
150 200 250 300 350
* Excluding R&D personnel expenses
Contents
- Consolidated Financial Results for the Fiscal Year Ended March 31, 2023
- Consolidated Financial Forecasts for the Year Ending March 31, 2024
- Review of Medium-Term Management Plan 2023
- Overview of Medium-Term Management Plan 2026
5
Consolidated Financial Forecasts for FY2024 (for the Year Ending March 31, 2024): Net Sales
(¥m) | Net sales | Y/Y | |
Reagents | 38,353 | ▲27,571 | |
▲41.8% | |||
Instruments | 2,019 | +643 | |
+46.8% | |||
CDMO | 9,914 | +1,713 | |
+20.9% | |||
Regenerative | 4,646 | +178 | |
medicine | +4.0% | ||
Gene analysis/ | 5,173 | +1,441 | |
testing & others | +38.6% | ||
Gene Therapy | 3,012 | +372 | |
+14.1% | |||
6 |
Reagents: In addition to expanding reagents for general research, strengthen BtoB customized products
Instruments: Expansion of cell analysis equipment and gene amplification equipment
CDMO: Strengthen One-stop system to suit the development stages, including quality tests, from small-scale
manufacturing to large-scale manufacturing for clinical use, and from analysis for R&D to clinical analysis under reliability assurance
Gene Therapy: Strengthen AM products in addition to RetroNectin®
Consolidated Financial Forecast for FY2024
(for the Year Ending March 31, 2024)
FY2024 | ||
(¥m) | Full-year | |
Net sales | 53,300 | |
Gross profit | 33,984 | |
Operating | 8,000 | |
profit | ||
R&D | 9,000 | |
expense | ||
7 |
Y/Y
▲24,842 ▲31.8%
▲10,780 ▲24.1%
▲12,541 ▲61.1%
+424
+4.9%
Gross profit
Operating profit
FY2023/03 205
Sales | ▲148 | ||||||||||
Difference in sales | |||||||||||
Composition | +32 | ||||||||||
CompositionDifference | |||||||||||
Foreign exchange | +8 | ||||||||||
Exchangedifferences | |||||||||||
RESEARCH AND | ▲4 | ||||||||||
R&D | |||||||||||
DEVELOPMENT | |||||||||||
COSTS | ▲10 | ||||||||||
Personnel*exp nses | |||||||||||
※ | |||||||||||
Other | ▲3 | ||||||||||
Other expenses | |||||||||||
FY2024 | 80 | ||||||||||
FY03/24 | |||||||||||
(¥100m) | |||||||||||
0 | 50 | 100 | 150 | 200 | 11 | ||||||
250 |
* Excluding R&D personnel expenses
Contents
- Consolidated Financial Results for the Fiscal Year Ended March 31, 2023
- Consolidated Financial Forecasts for the Year Ending March 31, 2024
- Review of Medium-Term Management Plan 2023
- Overview of Medium-Term Management Plan 2026
8
Medium-Term Management Plan 2023 significantly exceeded the quantitative performance targets
Medium-Term Management Plan 2023
(¥100m)
Net sales | 676 | 781 | 700 | ||||||||||||||||||||||
345 | Actual 460 | 394 | 426 | 500 | |||||||||||||||||||||
MP23 338 | 300 | ||||||||||||||||||||||||
289 | |||||||||||||||||||||||||
3 | |||||||||||||||||||||||||
(¥100m) | |||||||||||||||||||||||||
Operating income | |||||||||||||||||||||||||
205 | |||||||||||||||||||||||||
R&D expenses | |||||||||||||||||||||||||
200 | |||||||||||||||||||||||||
139 | |||||||||||||||||||||||||
65 | |||||||||||||||||||||||||
100 | 64 | ||||||||||||||||||||||||
62 | |||||||||||||||||||||||||
45 | |||||||||||||||||||||||||
55 | 58 | 61 | 63 | 85 | |||||||||||||||||||||
48 | |||||||||||||||||||||||||
0 | 38 | ||||||||||||||||||||||||
Actual | MP23Actual | MP23 Actual | MP23 | Actual | |||||||||||||||||||||
FY2020 | FY2021 | FY2022 | FY2023 | ||||||||||||||||||||||
9 | MP23: Medium-Term Management Plan 2023 |
- Earnings exceeded quantitative targets by a large margin, reaching record highs, thanks to rapid and intensive responses to COVID testing demand and vaccine- related projects.
FY2023 | Target | Results |
Operating | ¥6.5b | ¥20.5b |
income | ||
ROE | 6% | 15.4% |
- Issues such as the dissolution of alliances for clinical-development projects and the unachieved sales of devices and CDMO to meet forecasts remained
- Utilized upside earnings to strengthen R&D investment, capital investment, and human resources investment for future growth
- billion